176 related articles for article (PubMed ID: 23443946)
1. Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.
Butler MS; Ricciardelli C; Tilley WD; Hickey TE
Horm Cancer; 2013 Jun; 4(3):154-64. PubMed ID: 23443946
[TBL] [Abstract][Full Text] [Related]
2. Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome.
Butler MS; Yang X; Ricciardelli C; Liang X; Norman RJ; Tilley WD; Hickey TE
Fertil Steril; 2013 Jun; 99(7):2076-83.e1. PubMed ID: 23433514
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning of canine co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) and investigation of its ability to suppress androgen receptor signalling in androgen-independent prostate cancer.
Kato Y; Ochiai K; Michishita M; Azakami D; Nakahira R; Morimatsu M; Ishiguro-Oonuma T; Yoshikawa Y; Kobayashi M; Bonkobara M; Kobayashi M; Takahashi K; Watanabe M; Omi T
Vet J; 2015 Nov; 206(2):143-8. PubMed ID: 26346258
[TBL] [Abstract][Full Text] [Related]
4. Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client.
Trotta AP; Need EF; Butler LM; Selth LA; O'Loughlin MA; Coetzee GA; Tilley WD; Buchanan G
J Mol Endocrinol; 2012 Oct; 49(2):57-68. PubMed ID: 22693264
[TBL] [Abstract][Full Text] [Related]
5. Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines.
Kato Y; Ochiai K; Kawakami S; Nakao N; Azakami D; Bonkobara M; Michishita M; Morimatsu M; Watanabe M; Omi T
BMC Vet Res; 2017 Jun; 13(1):170. PubMed ID: 28599655
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation.
Trotta AP; Need EF; Selth LA; Chopra S; Pinnock CB; Leach DA; Coetzee GA; Butler LM; Tilley WD; Buchanan G
Int J Cancer; 2013 Dec; 133(12):2812-23. PubMed ID: 23740762
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor REIC/DKK-3 and co-chaperone SGTA: Their interaction and roles in the androgen sensitivity.
Ochiai K; Morimatsu M; Kato Y; Ishiguro-Oonuma T; Udagawa C; Rungsuriyawiboon O; Azakami D; Michishita M; Ariyoshi Y; Ueki H; Nasu Y; Kumon H; Watanabe M; Omi T
Oncotarget; 2016 Jan; 7(3):3283-96. PubMed ID: 26658102
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
9. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
10. The cochaperone SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) demonstrates regulatory specificity for the androgen, glucocorticoid, and progesterone receptors.
Paul A; Garcia YA; Zierer B; Patwardhan C; Gutierrez O; Hildenbrand Z; Harris DC; Balsiger HA; Sivils JC; Johnson JL; Buchner J; Chadli A; Cox MB
J Biol Chem; 2014 May; 289(22):15297-308. PubMed ID: 24753260
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
12. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
[TBL] [Abstract][Full Text] [Related]
13. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors.
Chadha S; Rao BR; Slotman BJ; van Vroonhoven CC; van der Kwast TH
Hum Pathol; 1993 Jan; 24(1):90-5. PubMed ID: 8418017
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
16. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC.
Xue Q; Lv L; Wan C; Chen B; Li M; Ni T; Liu Y; Liu Y; Cong X; Zhou Y; Ni R; Mao G
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1539-49. PubMed ID: 23857189
[TBL] [Abstract][Full Text] [Related]
18. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.
Bijsmans IT; Smits KM; de Graeff P; Wisman GB; van der Zee AG; Slangen BF; de Bruïne AP; van Engeland M; Sieben NL; Van de Vijver KK
Mod Pathol; 2011 Mar; 24(3):463-70. PubMed ID: 21102419
[TBL] [Abstract][Full Text] [Related]
19. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
20. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
